Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

1d ago, source:

Prior to joining Foghorn, Mr. Humer most recently held executive roles at Viridian Therapeutics, Inc., where he successfully led financial strategy and business development as the Chief Financial ...

FHTX Foghorn Therapeutics Inc.

2mon ago, source: Seeking Alpha

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin ...

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

1mon ago, source: Yahoo Finance

Investors might want to bet on Foghorn Therapeutics Inc. (FHTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Real-Time Update: Foghorn Therapeutics Inc (FHTX) Stock Navigates the Market with Up-to-Date Data

6d ago, source: newsheater

The stock of Foghorn Therapeutics Inc (FHTX) has seen a 13.48% increase in the past week, with a 22.32% gain in the past month, and a 41.09% flourish in the past quarter. The volatility ratio for the ...

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

1mon ago, source: Nasdaq

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

2mon ago, source: Zacks.com on MSN

Foghorn Therapeutics Inc. is part of the Zacks Medical - Drugs industry. Organogenesis (ORGO), another stock in the same industry, closed the last trading session 0.8% higher at $3.65. ORGO has ...

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

1mon ago, source: Yahoo Finance

March 07, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting ...

Foghorn Therapeutics Inc Ordinary Shares FHTX

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Foghorn Therapeutics Inc Ordinary Shares

24d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

1mon ago, source: Yahoo Finance

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago. These ...

FHTX Foghorn Therapeutics Inc.

2mon ago, source: Seeking Alpha

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin ...